# BioStem Technologies (BSEM) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/BSEM
## Company Profile
- Ticker: BSEM
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 2.25 USD
- Market cap: Not available USD
- Last updated: 2026-10-13
## Business Overview
### Perinatal Tissue Regenerative Medicine Company
BioStem Technologies develops, manufactures, and commercializes allograft products derived from perinatal tissue. Its products are used across multiple specialties, particularly surgical care and wound management.
### Processing Technology and Product Portfolio
The company uses proprietary BioRetain, CryoTek, and SteriTek processing methods intended to preserve the natural properties of donated tissue. Its brands include Neox, Clarix, VENDAJE, and American Amnion.
### Hospital Commercialization Transition
Following the acquisition of BioTissue surgical and wound-care assets, BioStem is building a broader hospital-focused commercial organization, expanding its direct sales team and group purchasing organization coverage. The release did not identify a specific asset-level clinical or regulatory catalyst.
## Why The Stock Is Moving

As of Oct 13, 2026, BSEM closed down 7.79% at $2.25. No new same-company headline was identified in the current news window.

## Future Catalysts

- BioStem Technologies’ catalysts are wound-care product adoption and any commercial update that shows the regenerative-medicine platform is scaling. The market will care about recurring demand.

## Recent News
- 2026-10-08 11:00 EST — [BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options](https://biopharmsignal.com/news/BSEM/biostem-technologies-ceo-and-coo-invest-1-million-in-cash-through-exercise-of-st-2ccc65f6) — Source: BioStem Technologies
- 2026-10-01 11:00 EST — [BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio](https://biopharmsignal.com/news/BSEM/biostem-technologies-strengthens-placental-allograft-and-umbilical-tissue-patent-c869622c) — Source: BioStem Technologies
- 2026-09-30 12:00 EST — [BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules](https://biopharmsignal.com/news/BSEM/biostem-technologies-announces-3-million-private-placement-priced-at-the-market--463c80db) — Source: BioStem Technologies
- 2026-09-18 11:00 EST — [BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility](https://biopharmsignal.com/news/BSEM/biostem-technologies-secures-up-to-40-million-in-a-committed-equity-facility-3832793f) — Source: BioStem Technologies
- 2026-09-04 11:00 EST — [BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier](https://biopharmsignal.com/news/BSEM/biostem-technologies-opens-hospital-access-for-vendaje-and-vendaje-ac-through-vi-6b49148f) — Source: BioStem Technologies